Results 31 to 40 of about 250 (109)

International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (iSPHYNCS): the impact of psychiatric comorbidities on daily life in central disorders of hypersomnolence—a vicious circle

Journal of Sleep Research, Volume 34, Issue 3, June 2025.
Summary Presence of psychiatric comorbidities is well documented in narcolepsy type‐1 (NT1) but there are limited data on patients with ‘other central disorders of hypersomnolence’ (OCH). This study aimed to investigate frequency of psychiatric comorbidities in patients with NT1 and OCH, and to evaluate their impact on quality of life and sleep as an ...
Merve Aktan Suzgun, Elena S. Wenz, Julia van der Meer, Livia G. Fregolente, Jan D. Warncke, Silvia Miano, Jens Acker, Mathias Strub, Elisabeth Olliges, Ramin Khatami, Markus H. Schmidt, iSPHYNCS Investigators, Claudio L. A. Bassetti, Sigrid von Manitius   +13 more
wiley   +1 more source

The electroretinography to identify biomarkers of idiopathic hypersomnia and narcolepsy type 1

Journal of Sleep Research, Volume 34, Issue 1, February 2025.
Summary Hypersomnia spectrum disorders are underdiagnosed and poorly treated due to their heterogeneity and absence of biomarkers. The electroretinography has been proposed as a proxy of central dysfunction and has proved to be valuable to differentiate certain psychiatric disorders.
Héloïse Rach, Ulker Kilic‐Huck, Pierre A. Geoffroy, Tristan Bourcier, Sophie Braun, Henri Comtet, Elisabeth Ruppert, Laurence Hugueny, Marc Hebert, Eve Reynaud, Patrice Bourgin   +10 more
wiley   +1 more source

Autonomic cardiovascular control is unaffected in children referred for assessment of excessive daytime sleepiness

Journal of Sleep Research, Volume 34, Issue 1, February 2025.
Summary There is conflicting evidence for impaired autonomic control of heart rate (HR) in adults with narcolepsy and idiopathic hypersomnolence (IH). Despite these chronic hypersomnia conditions primarily being diagnosed around the age of puberty, there are limited studies in children.
Jamilla Francis, Georgina Plunkett, Marisha Shetty, Margot J. Davey, Gillian M. Nixon, Lisa M. Walter, Rosemary S. C. Horne   +6 more
wiley   +1 more source

Loss of rapid eye movement atonia in rapid eye movement sleep behaviour disorder and narcolepsy

Journal of Sleep Research, Volume 34, Issue 1, February 2025.
Summary A reduction of physiological muscle atonia during rapid eye movement sleep is characteristic in patients with rapid eye movement sleep behaviour disorder, however, it can also be found in narcolepsy patients. We evaluated rapid eye movement sleep associated electromyographic activity to set cut‐off values of rapid eye movement sleep without ...
Franziska Edlinger, Marion Böck, Stefan Seidel, Karin Trimmel   +3 more
wiley   +1 more source

Sleep interventions in pediatric oncology: A systematic review of the evidence

Pediatric Blood &Cancer, Volume 71, Issue 10, October 2024.
Abstract Sleep concerns are common during pediatric cancer treatment and can last into survivorship. The current systematic review sought to identify intervention studies that addressed sleep as a primary or secondary outcome during pediatric cancer treatment up to 5 years after completing treatment.
Lauren C. Daniel, Corinne Catarozoli, Valerie McLaughlin Crabtree, Matthew Bridgeman, Raphaele van Litsenburg, Elin Irestorm   +5 more
wiley   +1 more source

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. [PDF]

CNS Drugs, 2022
Roth T, Dauvilliers Y, Thorpy MJ, Kushida C, Corser BC, Bogan R, Rosenberg R, Dubow J, Seiden D.   +8 more
europepmc   +1 more source

Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial. [PDF]

CNS Drugs
Roth T, Thorpy MJ, Kushida CA, Gudeman J.   +3 more
europepmc   +1 more source

Assessing Early Efficacy After Initiation of Once-Nightly Sodium Oxybate (ON-SXB; FT218) in Participants with Narcolepsy Type 1 or 2: A Post Hoc Analysis from the Phase 3 REST-ON Trial. [PDF]

CNS Drugs
Krahn L, Roy A, Winkelman JW, Morse AM, Gudeman J.   +4 more
europepmc   +1 more source

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment. [PDF]

Adv Ther, 2023
Morse AM, Krahn L, Flygare J, Kushida C, Thorpy MJ, Athavale A, Gudeman J.   +6 more
europepmc   +1 more source

Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia. [PDF]

J Clin Sleep Med, 2023
Morse AM, Dauvilliers Y, Arnulf I, Thorpy MJ, Foldvary-Schaefer N, Chandler P, Chen A, Hickey L, Black J, Bogan RK.   +9 more
europepmc   +1 more source